Merck's Surge Masks Underlying Issues

Merck's stock price has risen by 29.6% over the past six months, beating the S&P 500 by 13.4%. However, despite its strong performance, analysts from StockStory are cautious about investing in the company.

Their concerns stem from three key areas: weak constant currency growth, shrinking adjusted operating margin, and declining earnings per share (EPS). Constant currency revenue, which excludes the impact of currency fluctuations, averaged 3.8% year-over-year growth over the last two years, slightly lagging the sector. This may indicate that Merck needs to lower prices or invest in product improvements to accelerate growth, potentially hindering near-term profitability.

The adjusted operating margin has decreased by 19.9 percentage points over the last five years, raising questions about the company's expense base. Its EPS declined by 11.1% annually over the same period, despite revenue growing by 7.9%. This suggests that Merck became less profitable on a per-share basis as it expanded.

While Merck's valuation is reasonable at 17 times forward P/E, analysts do not see a significant buying opportunity at present. Instead, they recommend considering the entrenched endpoint security platform on the market.